2 Final-Studien (Brust & Leberkrebs) Mkap 35 M$

 

was meint ihr wo wir heute abend stehen werden?  

 

wird der Kurs nicht wieder gnadenlos runter geprügelt.  

hab mir gerade mal ne erste Posi ins Depot gelegt.  

mal sehen ob wir auf TH schließen.  

Umsatz ist ja schon mal was....

 

in der Nähe, geht am Montag die Post ordentlich UP!  

Short interest beachtlich
http://www.shortsqueeze.com/?symbol=clsn&submit=Short+Quote%99

Leider ist hier ausserbörslich der Spread zu hoch, mal sehen ob ich am Montag
noch mal nachkaufe

Schönes We
 

Achterbahnfahrt pur.

http://finance.yahoo.com/q?s=CLSN

 

sorgen schon dafür, daß das Teil nicht durchstartet.  

 

 

der Shortverein lässt nicht locker  

knallt es um so gewaltiger nach oben.

Short Interest (Shares Short)
11,518,000

Days To Cover (Short Interest Ratio)
8.1
 

Deals and Financings

Zhejiang Hisun Pharma (SHA: 600267) will raise up to 936 million RMB ($152.6 million) in a convertible bond offering. The company will use the money to build a manufacturing facility that will make finished drugs, in both solid form and injections. Hisun said the construction will move it further away from its traditional focus on APIs to become a pharmaceutical company with a broad range of offerings.

JenaValve Technology, a German company that has developed a transcatheter aortic valve implantation (TAVI) system to replace sclerotic aortic valves, raised $62.5 million in a Series C venture round. Part of the money will be allocated for China approval of the device. Legend Capital, the Beijing-based VC/PE firm, participated in the round.

4,374 people received this article by email alert
Add your email to get alerts on CLSN too:
Get email alerts on CLSN »This article was sent to 321,572 people who get the Investing Ideas newsletter. Get the Investing Ideas newsletter »  
Despite its well-publicized problems in China, GlaxoSmithKline (NYSE: GSK) is actively moving forward with a plan to form a vaccine collaboration with a China company (see story). The company revealed it is talking to several China vaccine makers, with the goal of forming an R&D/marketing partnership. Christophe Weber, head of GSK's vaccine division, said the conversations have not been affected by the on-going bribery scandal.

Zhejiang Hisun Pharma and Celsion (NSDQ: CLSN) of the US signed a new MOU that expands their collaboration on ThermoDox®, a heat-activated liposomal encapsulation of doxorubicin for primary liver cancer (see story). In June 2012, Celsion and Hisun signed a long-term commercial supply agreement for the production of ThermoDox. The new MOU calls for the two companies to conduct clinical trials of ThemoDox in China, develop new liposomal formulations, and transfer to Hisun the technology allowing commercial manufacture of ThermoDox.

Lumenis Ltd. struck a deal to distribute Visionix's ophthalmic and optometric diagnostics product line in China. Visionix's wavefront technology measures the way light passes through the eye, giving a precise diagnosis for corrective lenses or laser correction surgery. Lumenis is the world's largest medical laser company for ophthalmic, aesthetic and surgical applications. Both companies are headquartered in Israel.

Company News

http://seekingalpha.com/article/...ne-collaboration-plan?source=yahoo


BGI Shenzhen, the world's largest genomic institute, working with the Reproductive & Genetic Hospital CITIC-XIANGYA, has used Next Generation Sequencing (NGS) to analyze in vitro fertilized (IVF) embryos and detect any genetic abnormalities. After sequencing, only the best embryos of the cohort are implanted, thereby increasing pregnancy rates and reducing genetically caused abnormalities. BGI says that, by improving genetic screening, preimplantation sequencing advances the practice of human assisted reproduction.

As the result of its ongoing scandal in China, GlaxoSmithKline replaced its General Manager for China, Mark Reilly, with Herve Gisserot, who had been GSK's vice president for Europe. Mr. Reilly left China in late June when authorities raided GSK's offices. The trip was described as a routine visit to headquarters, but GSK officials refused to answer whether Mr. Reilly would be subject to arrest if he returned to China. GSK said there are "no allegations of wrongdoing" against Reilly, who was not fired.

Two years ago, an internal audit of practices at GlaxoSmithKline's Shanghai R&D facility showed serious problems (see story). Researchers did not report a total of six test results of a multiple sclerosis drug. By the time the tests were discovered, the drug, ozanezumab, was already being tested in humans. When GSK officials looked at the data, they stopped testing the drug in patients with MS, though trials for Lou Gherig's disease were allowed to continue
 

bis die Shorties wieder kommen.  

Wahrscheinlich Shorten die Herren dort kräftig mit.

http://seekingalpha.com/article/...5-years-is-not-enough?source=yahoo

Aber wir haben heute trotzdem Grün geschlossen!!!

Diskussionen auf Yahoo dazu

http://finance.yahoo.com/mb/CLSN/...fafc4d32ec82&mbtc=mb-tab-allt


 

jeden Tag das selbe Spiel  

Aber ich weiß genau, sobald ich verkaufe, fliegt das Teil

Hold  

Vielleicht kommt ja dann Bewegung in die richtige Richtung rein!  

http://www.ariva.de/news/...ts-and-Provides-HEAT-Study-Update-4742392



Jetzt müsste der Knoten platzen.
Über 11 Mio Shorts  

"Und täglich grüßt das Murmeltier" ;-)))  

landen wir noch im Minus  

Celsion Announces Official ThermoDox® HEAT Study Results to be presented at the International Liver Cancer Association (ILCA) 2013 Annual Conference in Washington, D.C. on September 14, 201314:05 21.08.13


PR Newswire

LAWRENCEVILLE, N.J., Aug. 21, 2013

LAWRENCEVILLE, N.J., Aug. 21, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that Ronnie T.P. Poon, MD, MS, PhD, FRCS (Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion's Phase III HEAT Study of ThermoDox® in hepatocellular carcinoma (HCC) will present the official clinical trial results from the HEAT Study at the International Liver Cancer Association 7th Annual Conference being held September 13-15, 2013 in Washington D.C.  Following the presentation on September 14, 2013, the Company is sponsoring a symposium of leading liver cancer experts to discuss new directions in the treatment of early-intermediate HCC.

•Professor Poon's oral presentation, titled "Phase 3 Randomized, Double-Blind, Dummy-Controlled Trial of Radiofrequency Ablation (RFA) + Lyso-Thermosensitive Liposomal Doxorubicin for Hepatocellular Carcinoma (HCC) Lesions 3-7 cm," will be held on September 14, 2013 at 12:00 p.m. (local time) during the Plenary Session.  ILCA has selected the HEAT Study presentation to be webcast as part of an online educational program of the ILCA 2013 Annual Conference.  Professor Poon's presentation will be made available online after the conference.




•Professor Poon's presentation will include the most recent overall survival data.  Recent HEAT Study post-hoc analysis, strongly suggest positive progression-free survival (PFS) and overall survival (OS) in ThermoDox® treated patients when heating cycles from the radiofrequency ablation (RFA) procedure were optimized. Celsion has conducted a comprehensive analysis of the data from the Phase III HEAT Study of ThermoDox® in HCC, also known as primary liver cancer.  Subgroup analysis based on RFA heating duration continues to suggest that ThermoDox® markedly improves Overall Survival, when compared to the control group, in patients if their lesions undergo RFA for 45 minutes or more.  These findings apply to single HCC lesions (63% of the HEAT Study population) from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent approximately 300 patients.




•Celsion is sponsoring a symposium in conjunction with the ILCA conference moderated by Professor Riccardo Lencioni, MD, FSIR, EBIR, the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy.   Participants will include Professor Josep Llovet, MD, PhD, Professor of Medicine and Director, Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine; Ghassan K. Abou-Alfa MD, PhD, Associate Attending Memorial Sloan-Kettering Cancer Center, New York, NY, Associate Professor, Weill Medical College at Cornell University, New York, NY, and Associate Professor, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY ; and Professor Ronnie Poon, MD, PhD.  The discussion will focus on a review of new developments in the treatment of early-intermediate HCC and discuss updated data from the HEAT Study post-hoc analysis.  The Company will also have an Exhibit Booth (#2) at the ILCA conference to meet with attendees.
The International Liver Cancer Association is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines – medical, interventional and surgical oncology as well as hepatology.  ILCA's Executive Committee consists of Dr. Josep M. Llovet (President); Professor Riccardo Lencioni and Dr. Morris Sherman.  Celsion notes that Professors Lencioni and Poon and Dr. Sherman are principal investigators on the HEAT Study.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.  Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Senior Vice President and

Chief Financial Officer

609-482-2455

jchurch@celsion.com

SOURCE Celsion Corporation


Quelle: PR Newswire